Verge Genomics to advance its inhibitors of PIKfyve for the treatment...
Verge Genomics announced this week at BIO International its lead program for amyotrophic lateral sclerosis (ALS) is the endosomal lipid kinase, PIKfyve, with plans to enter clinical trials next year....(PRWeb June 11, 2020)Read the full story at https://www.prweb.com/releases/verge_genomics_to_advance_its_inhibitors_of_pikfyve_for_the_treatment_of_als_and_covid_19/prweb17178507.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2020 Category: Pharmaceuticals Source Type: news
Researchers identify new genetic defect linked to ALS
(University of Maryland School of Medicine) Researchers at the University of Maryland School of Medicine (UMSOM) have identified how certain gene mutations cause amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The pathway identified by the researchers may also be responsible for a certain form of dementia related to ALS. The finding could offer potential new approaches for treating this devastating condition. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2020 Category: International Medicine & Public Health Source Type: news
Researchers conduct metabolite analysis of ALS patient blood plasma
(North Carolina State University) High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS). The work sheds further light on a pathway involved in disease progression and appears to rule out an environmental neurotoxin as playing a role in ALS. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 29, 2020 Category: Biology Source Type: news
Genetic doppelgaengers: Emory research provides insight into two neurological puzzles
(Emory Health Sciences) Insight into the pathological mechanisms behind two devastating neurodegenerative diseases: the most common inherited form of amyotrophic lateral sclerosis/ frontotemporal dementia (ALS/FTD) and spinocerebellar ataxia type 36 (SCA36). Expanded repeats lead to peptide gobbledygook in both, but with critical differences. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
VANCOUVER, British Columbia, April 30, 2020 -- (Healthcare Sales & Marketing Network) -- Alpha Cognition Inc. (ACI) today announced that in a pre-Investigational New Drug (Pre-IND) meeting, the U.S. Food and Drug Administration (USFDA) agreed upon a clini... Biopharmaceuticals, Neurology, FDA Alpha Cognition, Alzheimer's Disease, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news
Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models
(University of Toronto) Scientists have delayed the onset of amyotrophic lateral sclerosis (ALS) in laboratory models, leaving them cautiously optimistic that the result, combined with other clinical advances, points to a potential treatment for ALS in humans. The researchers targeted neurons in the brain's motor cortex with an engineered protein that prevented their degeneration and delayed the onset of symptoms such as hardening of the neuron's myelin sheath, weight loss and a deterioration in motor skills. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 20, 2020 Category: International Medicine & Public Health Source Type: news
Caring for Relatives With ALS Almost a Full-Time Job for Youth: Study
FRIDAY, March 27, 2020 -- Kids and teens spend as much as five hours a day helping care for relatives with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig ' s disease, a new study finds.
Although the young people often help with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2020 Category: General Medicine Source Type: news
Scientists identify gene that first slows, then accelerates, progression of ALS in mice
(The Zuckerman Institute at Columbia University) Columbia scientists have provided new insights into how mutations in a gene called TBK1 cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that robs patients of movement, speech and ultimately, their lives. The researchers found that ALS-associated mutations in TBK1 can have both positive and negative effects on the progression of disease in mice genetically modified to have ALS-like symptoms. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 27, 2020 Category: Biology Source Type: news
Comparison of driving capacity among patients with amyotrophic lateral sclerosis and healthy controls using the lane change task - Hayes HA, Hu N, Wang X, Gibson S, Mathy P, Berggren K, Bromberg M.
OBJECTIVE: Compare driving capacity of individuals with Amyotrophic Lateral Sclerosis (ALS) and healthy controls (HC) using a driving simulation program. METHODS: A prospective study was performed on individuals with ALS who reported they were stil... (Source: SafetyLit)
Source: SafetyLit - March 11, 2020 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
New CRISPR base-editing technology slows ALS progression in mice
(University of Illinois at Urbana-Champaign, News Bureau) With a new CRISPR gene-editing methodology, scientists from the University of Illinois at Urbana-Champaign inactivated one of the genes responsible for an inherited form of amyotrophic lateral sclerosis -- a debilitating and fatal neurological disease for which there is no cure. The novel treatment slowed disease progression, improved muscle function and extended lifespan in mice with an aggressive form of ALS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 26, 2020 Category: International Medicine & Public Health Source Type: news
New Disability Scale Better Assesses ALS Outcomes New Disability Scale Better Assesses ALS Outcomes
A new amyotrophic lateral sclerosis (ALS) disability scale (ROADS) that uses the mathematically rigorous Rasch methodology outperforms the revised ALS Functional Rating Scale (ALSFRS-R) in measuring ALS patient-reported outcomes, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Amylyx drug helps slow ALS progression in mid-stage study
Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Top 10 Health Questions America Asked Dr. Google In 2019
(CNN) — Google users in the United States had a lot of questions about blood pressure, the keto diet and hiccups in 2019.
Those topics were among the 10 most-searched health-related questions on the search engine this year, according to new data from Google.
The list was based on search terms collected between January and early December.
Last year, the top health-related questions Googled by people in the US included what is amyotrophic lateral sclerosis, or ALS, what is endometriosis and how long does weed stay in your urine.
In 2017, what is lupus, how long does the flu last and what causes hiccups were some of the...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 12, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Google Source Type: news
Emerging role of adenosine in brain disorders and amyotrophic lateral sclerosis
(Mary Ann Liebert, Inc./Genetic Engineering News) The role of adenosine in neurodegeneration and neuroregeneration has led to growing attention on adenosine receptors as potential drug targets in a range of brain disorders, including neuroregenerative therapy and treatment for amyotrophyic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 6, 2019 Category: International Medicine & Public Health Source Type: news
FDA Clears Oral Film Formulation of ALS Drug Riluzole (Exservan) FDA Clears Oral Film Formulation of ALS Drug Riluzole (Exservan)
An oral film formulation of riluzole may help overcome challenges of disease-related dysphagia in patients with amyotrophic lateral sclerosis.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 26, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
